Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03822351

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC — COAST  

Stage III Non-small Cell Lung Cancer Clinical Trial

Official title:
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Clinical Trial Summary

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Clinical Trial Description

Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03822351
Study type Interventional
Source MedImmune LLC
Contact
Status Completed
Phase Phase 2
Start date December 19, 2018
Completion date July 18, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05488626 - Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer N/A
Recruiting NCT02076282 - MRI Optimization Study in Stage III NSCLC N/A
Terminated NCT01577212 - Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy Phase 2
Withdrawn NCT01336543 - Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01102231 - Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT06082492 - The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients N/A
Active, not recruiting NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Phase 2
Recruiting NCT03077854 - Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial N/A
Recruiting NCT05157542 - Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC Phase 1
Recruiting NCT00938418 - Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05361174 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03048500 - Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Not yet recruiting NCT05891080 - Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial Phase 2
Active, not recruiting NCT01948141 - Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Phase 2
Completed NCT01282437 - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC Phase 3
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Recruiting NCT05157503 - Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
Recruiting NCT05468242 - Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Active, not recruiting NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC Phase 2